I. Treatment of diseases or conditions affecting the performance or activity of methylene acrylic acid/9 (PCSK9) acrylonitrile； antibodies or single fragments specifically binding to methylene acrylic acid/9 (PC) transformants Page: 1
The present invention relates to Pharmaceutical compositions comprising an antibody specifically binding to human proprotein convertase subtilisin/kexin type 9 (PCSK9), to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. The present invention also relates to articles of manufacture comprising packaging material, PCSK9-specific antibodies or antigen-binding fragments thereof, and a label or packaging insert indicating which groups of patients can be treated with said antibodies or fragments, which groups of patients must not be treated with said antibodies or fragments, and which dosage regimen should be used. The present invention further relates to methods of testing the efficacy of PCSK9-specific antibodies or antigen-binding fragments thereof for the treatment of certain diseases or conditions and for the treatment of specific sub-groups of patients.METODO PARA TRATAR ENFERMEDAD O AFECCIÓN EN EL QUE LA EXPRESIÓN O LA ACTIVIDAD DE LA PROPROTEÍNA CONVERTASA SUBTILISINA/KEXINA TIPO 9 (PCSK9) OCASIONAN UN IMPACTO； ANTICUERPO O FRAGMENTO DE UNIÓN AL ANTÍGENO QUE SE UNE ESPECÍFICAMENTE A LA PROPROTEÍNA CONVERTASA SUBTILISINA/KEXINA TIPO 9 (PCSK9).
